Max Weight Loss20.9%
Studies12
Participants8,750
StatusAvailable
Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Complete Research Database
Clinical Research Outcomes
SURMOUNT-1
Female, 45, BMI 38
Lost 68 pounds (22% body weight) in 72 weeks
“Energy levels improved dramatically after week 8. GI side effects were manageable during first month.”
Also saw improvements in joint pain and sleep quality
SURPASS-2
Male, 52, T2DM + Obesity
HbA1c dropped from 8.1% to 5.8%, lost 45 pounds
“Blood sugar control was remarkable. Reduced diabetes medications significantly.”
Discontinued two diabetes medications under medical supervision
SURMOUNT-4
Female, 38, Prediabetes
Prevented diabetes progression, 15% weight loss maintained
“Three years later, still diabetes-free and maintaining weight loss with continued treatment.”
Initially lost 42 pounds, maintained 85% of weight loss at 3 years
Clinical Outcome Measures
+20.9
⚖️ Weight Reduction
(from 3.1 baseline)
+2.3
🍯 HbA1c Control
(from 0.2 baseline)
+15.0
💗 Cardiovascular
(from 2.0 baseline)
+35.8
😊 Quality of Life
(from 12.1 baseline)
+68.4
🕒 Meal Satisfaction
(from 15.2 baseline)
Clinical outcome measures
Cardiovascular & Metabolic Outcomes
Blood Pressure Reduction
-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs
Triglycerides
-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement
HDL Cholesterol
+8.3% increase
Statistical significance: p<0.01
Improved lipid profile
Waist Circumference
-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity
C-Reactive Protein
-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation
Sleep Apnea Events
-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.